Adverse Events Module

Adverse Events Module

For researchers submitting trial data to ClinicalTrials.gov, the Adverse Events module is one of four mandatory results sections. It requires reporting in three primary categories: All-Cause Mortality: A table tracking all deaths that occurred during the study, regardless of cause. Serious Adverse Events (SAEs): A tabular summary of events resulting in death, life-threatening conditions, hospitalization, or significant disability. Other Adverse Events: A table for non-serious events that exceed a specific frequency threshold, such as 5% within any study arm.

Adverse Events Module path is as follows:

Study -> Results Section -> Adverse Events Module -> Event Groups

Study -> Results Section -> Adverse Events Module -> Serious Events

Study -> Results Section -> Adverse Events Module -> Other Events

Adverse Events Module


Ignite Creation Date: 2025-12-25 @ 2:13 AM
Ignite Modification Date: 2025-12-26 @ 12:41 AM
NCT ID: NCT01703260
Description: At each visit the investigator had to document any occurrence of adverse events and abnormal laboratory findings. Any event spontaneously reported by the participant or observed by the investigator was recorded, irrespective of the relation to study treatment.
Frequency Threshold: 0
Time Frame: Treatment-emergent AEs will be defined as any AEs, regardless of relationship to study drug, that occur or worsen after the first dose of double-blinded study drug and no more than 30 days after the last dose of study drug.
Study: NCT01703260
Study Brief: Safety and Efficacy of Roflumilast and Pioglitazone in Treating Adults With Nonalcoholic SteatoHepatitis
Event Groups(If Any):

Event Groups

Title Description Deaths # Affected Deaths # At Risk Serious # Affected Serious # At Risk Other # Affected Other # At Risk View
Roflumilast + Pioglitazone Roflumilast, 500 microgram (mcg), tablet, orally, once daily and pioglitazone, 30 milligram (mg), tablet, orally, once daily for up to 4 months. None None 0 7 5 7 View
Roflumilast Only Roflumilast, 500 mcg, tablet, orally, once daily and pioglitazone placebo-matching tablet, orally, once daily for up to 4 months. None None 0 7 4 7 View
Pioglitazone Only Pioglitazone, 30 mg, tablet, orally, once daily and roflumilast placebo-matching tablet, orally, once daily for up to 4 months. None None 0 6 4 6 View
Serious Events(If Any):
Other Events(If Any):

Other Events

Term Type Organ System Vocab View
Insomnia SYSTEMATIC_ASSESSMENT Psychiatric disorders MedDRA (17.0) View
Diarrhoea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (17.0) View
Nausea SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (17.0) View
Vomiting SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (17.0) View
Dyspepsia SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (17.0) View
Eructation SYSTEMATIC_ASSESSMENT Gastrointestinal disorders MedDRA (17.0) View
Chills SYSTEMATIC_ASSESSMENT General disorders MedDRA (17.0) View
Fatigue SYSTEMATIC_ASSESSMENT General disorders MedDRA (17.0) View
Pyrexia SYSTEMATIC_ASSESSMENT General disorders MedDRA (17.0) View
Influenza SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (17.0) View
Urinary tract infection SYSTEMATIC_ASSESSMENT Infections and infestations MedDRA (17.0) View
Liver function test abnormal SYSTEMATIC_ASSESSMENT Investigations MedDRA (17.0) View
Weight decreased SYSTEMATIC_ASSESSMENT Investigations MedDRA (17.0) View
Decreased appetite SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders MedDRA (17.0) View
Cow's milk intolerance SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders MedDRA (17.0) View
Increased appetite SYSTEMATIC_ASSESSMENT Metabolism and nutrition disorders MedDRA (17.0) View
Myalgia SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (17.0) View
Pain in extremity SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (17.0) View
Arthralgia SYSTEMATIC_ASSESSMENT Musculoskeletal and connective tissue disorders MedDRA (17.0) View
Headache SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (17.0) View
Paraesthesia SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (17.0) View
Sciatica SYSTEMATIC_ASSESSMENT Nervous system disorders MedDRA (17.0) View
Cough SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (17.0) View
Nasal congestion SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (17.0) View
Rhinorrhoea SYSTEMATIC_ASSESSMENT Respiratory, thoracic and mediastinal disorders MedDRA (17.0) View